Sanofi announces buy back of shares from L’Oréal
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...
The deal will diversify the French beauty giant’s funding sources at a time when the industry is undergoing a slowdown.
Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...
We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results